Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 74

recruiting
3 987
countries
28
conditions
2 109

1 063 trials match your criteria

Bladder transitional cell carcinoma

Not recruiting

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab

Non-small cell lung cancer

Not recruiting

Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Carbonate

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Pembrolizumab, Canakinumab, and Chemotherapy for Untreated Advanced Non-Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Canakinumab

Non-small cell lung cancer stage III

Not recruiting

Study on Osimertinib for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib

Non-small cell lung cancer

Not recruiting

Study of Chemotherapy and Nivolumab for Patients with Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Non-small cell lung cancer

Not recruiting

Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Systemic lupus erythematosus+3

Not recruiting

Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Crovalimab

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab

Pancreatic carcinoma metastatic

Not recruiting

Study of Zolbetuximab with Nab-Paclitaxel and Gemcitabine for Adults with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.